20/20 BioLabs Q1 revenue $0.4M, net loss $2.2M; expects Q2 rebound from firefighter programs

20/20 Biolabs, Inc.

2026-Q1 EPS reported -$0.28 revenue$353,375

Q1 revenue $0.4M vs $0.6M YoY; net loss $2.2M vs $0.8M; gross margin 17.8% vs 29.9%.
Cash $4.2M (vs $1.0M Dec 2025) after $5M private placement; deferred revenue $0.5M.
State-funded firefighter cancer screening programs expected to drive meaningful Q2 revenue; second state committed.
Launched OneTest for Longevity with IBM; exclusive U.S. CKD license from ROKIT Healthcare.
Medicare MCED Screening Act signed Feb 2026; pathway for Medicare coverage by 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

20/20 Biolabs, Inc. reported the first quarter ended March 31, 2026 results: revenue $0.4 million.

Period: the first quarter ended March 31, 2026
Revenue: $0.4 million
Result: reported results

Exact text from the filing

Total revenue for the three months ended March 31, 2026 was $0.4 million, compared to $0.6 million

View on SEC.gov

Browse all earnings releases →

20/20 Biolabs, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-059526

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.